Holen Sie sich die Stockscreener-App
3.17
16.12%
0.44
Schlusskurs vom Vortag:
$2.73
Offen:
$2.78
24-Stunden-Volumen:
1.66M
Relative Volume:
1.42
Marktkapitalisierung:
$201.47M
Einnahmen:
$149.50M
Nettoeinkommen (Verlust:
$-74.62M
KGV:
-2.678
EPS:
-1.1837
Netto-Cashflow:
$-82.95M
1W Leistung:
+6.38%
1M Leistung:
+65.10%
6M Leistung:
+92.12%
1J Leistung:
+77.09%
1-Tages-Spanne:
$2.78
$3.21
1-Wochen-Bereich:
$2.71
$3.21
52-Wochen-Spanne:
$0.9897
$3.54
Macrogenics Inc Stock (MGNX) Company Profile
Firmenname
Macrogenics Inc
Sektor
Branche
Telefon
301-251-5172
Adresse
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
3.17 | 201.47M | 149.50M | -74.62M | -82.95M | -1.1837 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2024-11-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-31 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-05-10 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Herabstufung | Stifel | Buy → Hold |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-04-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-04-09 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-03-04 | Bestätigt | BTIG Research | Buy |
| 2024-02-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-11-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-11-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-02-28 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-02-04 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Buy |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Hochstufung | Barclays | Underweight → Overweight |
| 2020-12-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2019-12-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Guggenheim | Neutral |
| 2019-02-07 | Hochstufung | Citigroup | Sell → Buy |
| 2019-02-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-02-06 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-12-10 | Herabstufung | Raymond James | Outperform → Underperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-05-31 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-31 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Macrogenics Inc Aktie (MGNX) Neueste Nachrichten
Treasury Yields: Can MacroGenics Inc disrupt its industry2026 AllTime Highs & Verified High Yield Trade Plans - baoquankhu1.vn
Patterns Watch: What is the next catalyst for MacroGenics IncCEO Change & Fast Exit Strategy with Risk Control - baoquankhu1.vn
VIX Spike: Can MacroGenics Inc be the next market leaderTrade Entry Summary & AI Driven Stock Price Forecasts - baoquankhu1.vn
Highs Report: How does MacroGenics Inc compare to its peers2026 Volume & Weekly High Momentum Picks - baoquankhu1.vn
MacroGenics (NASDAQ:MGNX) Share Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Why is MacroGenics stock sinking Tuesday? - MSN
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
Sentiment Review: Will MacroGenics Inc outperform the market in YEAR2026 Big Picture & Fast Gain Stock Tips - baoquankhu1.vn
Bull Run: Is MacroGenics Inc attractive for institutional investorsWeekly Stock Analysis & Verified Momentum Watchlists - baoquankhu1.vn
MacroGenics Inc earnings missed by $0.03, revenue topped estimates - Investing.com Nigeria
MacroGenics (NASDAQ:MGNX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Who's Buying or Selling Macrogenics Inc (HAM:M55) Stock Today? - GuruFocus
Macrogenics Inc (HAM:M55) DCF Valuation - GuruFocus
MacroGenics at Barclays Conference: Strategic Therapeutic Focus By Investing.com - Investing.com Canada
MGNX: Multiple clinical milestones and strategic updates expected in 2026, backed by strong partnerships - TradingView
MacroGenics (NASDAQ:MGNX) Price Target Raised to $4.00 at Barclays - Defense World
Macrogenics receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Australia
MacroGenics (MGNX) Loss Of US$74.6 Million Tests Bullish Loss‑Narrowing Narrative - simplywall.st
Stifel reiterates MacroGenics stock rating with $4 price target By Investing.com - Investing.com Canada
Stifel reiterates MacroGenics stock rating with $4 price target - Investing.com India
MacroGenics at Leerink Global Healthcare Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Cartesian Therapeutics (RNAC) - The Globe and Mail
MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies - Asianet Newsable
MGNX: Focused execution and pipeline progress set up major clinical milestones for mid-2026 - TradingView
Barclays Forecasts Strong Price Appreciation for MacroGenics (NASDAQ:MGNX) Stock - MarketBeat
MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS - MarketBeat
Barclays Raises Price Target for Macrogenics (MGNX) to $4.00, Ma - GuruFocus
MacroGenics, Inc. 2025 Annual Report: Innovative Antibody-Based Cancer Therapeutics, Pipeline, and Risk Factors Overview - Minichart
MacroGenics Q4 2025 Earnings: Loss Below Estimates, Revenue Beats ForecastNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures - Bitget
MacroGenics: Fourth Quarter Earnings Overview - Bitget
MacroGenics: Q4 Earnings Snapshot - marketscreener.com
MacroGenics : Corporate Overview March 2026 - marketscreener.com
MacroGenics (NASDAQ: MGNX) details 2025 results, cash runway and key 2026 data - Stock Titan
MacroGenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Chipmakers Recap: Can MacroGenics Inc expand its profit margins2026 Macro Moves & Low Risk Growth Stock Ideas - baoquankhu1.vn
Aug Breakouts: Can MacroGenics Inc disrupt its industryPortfolio Value Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
MacroGenics Q1 2025 Earnings Preview - MSN
Risk Off: Will MacroGenics Inc. stock deliver consistent dividends2025 Growth vs Value & Detailed Earnings Play Strategies - Naître et grandir
Aug Retail: Will MacroGenics Inc outperform the market in YEARJuly 2025 Macro Moves & Long-Term Growth Plans - baoquankhu1.vn
Trade Recap: Can MacroGenics Inc expand its profit marginsWeekly Volume Report & Long-Term Growth Stock Strategies - baoquankhu1.vn
MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts - MarketBeat
MGNX SEC FilingsMacrogenics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
MGNX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MacroGenics at TD Cowen Conference: Strategic Imperatives in Focus - Investing.com
MacroGenics (MGNX) director Jay Siegel to step down after 2026 meeting - Stock Titan
MacroGenics, Inc. Announces Jay Siegel Not Stands for Re-Election as Class I Director, Effective February 25, 2026 - marketscreener.com
Whats the profit margin of MacroGenics IncEarnings Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates C - GuruFocus
MacroGenics to Participate in Upcoming Investor Conferences - The Manila Times
Finanzdaten der Macrogenics Inc-Aktie (MGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):